2026-08-29T14:05:17Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/231812024-11-28T20:33:01Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Tait, Jessica R author Bilal, Hajira author Kim, Tae Hwan author Oh, Abigail author Peleg, Anton Y author Boyce, John D author Oliver, Antonio author Bergen, Phillip J author Nation, Roger L author Landersdorfer, Cornelia B author 2021-09 Objectives: Hypermutable Pseudomonas aeruginosa strains are a major challenge in cystic fibrosis. We investigated bacterial killing and resistance emergence for approved ceftazidime and tobramycin regimens, alone and in combination. Methods: Pseudomonas aeruginosa PAO Delta mutS and six hypermutable clinical isolates were examined using 48-h static concentration time-kill (SCTK) studies (inoculum similar to 10(7.5) CFU/mL); four strains were also studied in a dynamic in vitro model (IVM) (inoculum similar to 10(8) CFU/mL). The IVM simulated concentration-time profiles in epithelial lining fluid following intravenous administration of ceftazidime (3 g/day and 9 g/day continuous infusion), tobramycin (5 mg/kg and 10 mg/kg via 30-min infusion 24-hourly; half-life 3.5 h), and their combinations. Time courses of total and less-susceptible populations were determined. Results: Ceftazidime plus tobramycin demonstrated synergistic killing in SCTK studies for all strains, although to a lesser extent for ceftazidime-resistant strains. In the IVM, ceftazidime and tobramycin monotherapies provided <= 5.4 and <= 3.4 log(10) initial killing, respectively; however, re-growth with resistance occurred by 72 h. Against strains susceptible to one or both antibiotics, high-dose combination regimens provided >6 log(10) initial killing, which was generally synergistic from 8-24 h, and marked suppression of re-growth and resistance at 72 h. The time course of bacterial density in the IVM was well described by mechanism-based models, enabling Monte Carlo simulations (MCSs) to predict likely effectiveness of the combination in patients. Conclusion: Results of the IVM and MCS suggested antibacterial effect depends both on the strain's susceptibility and hypermutability. Further investigation of the combination against hypermutable P. aeruginosa strains is warranted. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. Tait JR, Bilal H, Kim TH, Oh A, Peleg AY, Boyce JD, et al. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. J Glob Antimicrob Resist. 2021 Sep;26:55-63. 10.1016/j.jgar.2021.04.021 2213-7173 2213-7165 Journal of Global Antimicrobial Resistance https://hdl.handle.net/20.500.13003/19746 34023531 L2013114279 2-s2.0-85108239921 https://hdl.handle.net/20.500.12105/23181 696999800012 Pharmacokinetics Pharmacodynamics Optimised dosing Antibiotic combination Dynamic in vitro infection model Mathematical modelling Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model